6.08
price up icon9.75%   0.54
after-market After Hours: 6.21 0.13 +2.14%
loading
Phathom Pharmaceuticals Inc stock is traded at $6.08, with a volume of 1.65M. It is up +9.75% in the last 24 hours and up +5.56% over the past month. Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
See More
Previous Close:
$5.54
Open:
$5.675
24h Volume:
1.65M
Relative Volume:
1.50
Market Cap:
$397.63M
Revenue:
-
Net Income/Loss:
$-297.11M
P/E Ratio:
-1.1715
EPS:
-5.19
Net Cash Flow:
$-216.95M
1W Performance:
+21.60%
1M Performance:
+5.56%
6M Performance:
-67.52%
1Y Performance:
-29.47%
1-Day Range:
Value
$5.47
$6.16
1-Week Range:
Value
$4.07
$6.16
52-Week Range:
Value
$4.07
$19.71

Phathom Pharmaceuticals Inc Stock (PHAT) Company Profile

Name
Name
Phathom Pharmaceuticals Inc
Name
Phone
(877) 742-8466
Name
Address
100 CAMPUS DRIVE,, FLORHAM PARK, NJ
Name
Employee
427
Name
Twitter
Name
Next Earnings Date
2024-11-07
Name
Latest SEC Filings
Name
PHAT's Discussions on Twitter

Compare PHAT with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
PHAT
Phathom Pharmaceuticals Inc
6.08 397.63M 0 -297.11M -216.95M -5.19
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
512.52 131.61B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
672.36 73.51B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
619.97 37.67B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
253.44 32.81B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
266.26 28.62B 3.81B -644.79M -669.77M -6.24

Phathom Pharmaceuticals Inc Stock (PHAT) Upgrades & Downgrades

Date Action Analyst Rating Change
Feb-14-25 Initiated Cantor Fitzgerald Overweight
May-03-24 Initiated Stifel Buy
Jan-05-24 Reiterated Needham Buy
Aug-09-23 Initiated H.C. Wainwright Buy
May-11-23 Upgrade Evercore ISI In-line → Outperform
Mar-13-23 Initiated Craig Hallum Buy
Oct-21-22 Initiated Jefferies Buy
May-06-22 Downgrade Evercore ISI Outperform → In-line
May-12-21 Upgrade Goldman Sell → Neutral
Feb-17-21 Initiated BMO Capital Markets Outperform
Feb-02-21 Initiated Guggenheim Buy
Jun-26-20 Downgrade Goldman Neutral → Sell
Nov-20-19 Initiated Evercore ISI Outperform
Nov-19-19 Initiated Goldman Neutral
Nov-19-19 Initiated Jefferies Buy
Nov-19-19 Initiated Needham Buy
View All

Phathom Pharmaceuticals Inc Stock (PHAT) Latest News

pulisher
03:46 AM

Jefferies cuts Phathom Pharmaceuticals target to $13 By Investing.com - Investing.com UK

03:46 AM
pulisher
02:23 AM

Jefferies Cuts Price Target on Phathom Pharmaceuticals to $13 From $17, Maintains Buy Rating - Marketscreener.com

02:23 AM
pulisher
Mar 13, 2025

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Receives $22.17 Average Price Target from Brokerages - Defense World

Mar 13, 2025
pulisher
Mar 12, 2025

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Shares Purchased by Keybank National Association OH - Defense World

Mar 12, 2025
pulisher
Mar 11, 2025

Phathom Pharmaceuticals stock hits 52-week low at $4.34 - Investing.com

Mar 11, 2025
pulisher
Mar 11, 2025

Phathom Pharmaceuticals stock hits 52-week low at $4.34 By Investing.com - Investing.com Australia

Mar 11, 2025
pulisher
Mar 11, 2025

Insider Buying: Asit Parikh Acquires 10,000 Shares of Phathom Ph - GuruFocus.com

Mar 11, 2025
pulisher
Mar 11, 2025

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT): Are Analysts Optimistic? - Simply Wall St

Mar 11, 2025
pulisher
Mar 11, 2025

Phathom Pharmaceuticals (NASDAQ:PHAT) Price Target Lowered to $12.00 at The Goldman Sachs Group - Defense World

Mar 11, 2025
pulisher
Mar 10, 2025

Phathom Pharmaceuticals’ Earnings Call: Growth and Challenges - TipRanks

Mar 10, 2025
pulisher
Mar 10, 2025

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Q4 2024 Earnings Call Transcript - Insider Monkey

Mar 10, 2025
pulisher
Mar 09, 2025

Phathom Pharmaceuticals, Inc. (PHAT) Reports Q4 Loss, Tops Revenue Estimates - MSN

Mar 09, 2025
pulisher
Mar 09, 2025

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Position Boosted by Rhumbline Advisers - Defense World

Mar 09, 2025
pulisher
Mar 09, 2025

Phathom Pharmaceuticals (NASDAQ:PHAT) Earns Buy Rating from HC Wainwright - Defense World

Mar 09, 2025
pulisher
Mar 08, 2025

Phathom Pharmaceuticals (NASDAQ:PHAT) Earns Buy Rating from Needham & Company LLC - Defense World

Mar 08, 2025
pulisher
Mar 07, 2025

Phathom Pharmaceuticals price target lowered to $12 from $18 at Goldman Sachs - TipRanks

Mar 07, 2025
pulisher
Mar 07, 2025

Phathom Pharmaceuticals price target lowered to $19 from $27 at Craig-Hallum - TipRanks

Mar 07, 2025
pulisher
Mar 07, 2025

H.C. Wainwright maintains $28 target on Phathom Pharma stock By Investing.com - Investing.com Canada

Mar 07, 2025
pulisher
Mar 07, 2025

H.C. Wainwright maintains $28 target on Phathom Pharma stock - Investing.com

Mar 07, 2025
pulisher
Mar 07, 2025

Phathom Pharmaceuticals: Strategic Positioning and Growth Potential in GERD Market Drives Buy Rating - TipRanks

Mar 07, 2025
pulisher
Mar 07, 2025

Phathom Pharmaceuticals Inc (PHAT) Q4 2024 Earnings Call Highlights: FDA Approval Boosts ... - Yahoo Finance

Mar 07, 2025
pulisher
Mar 06, 2025

Phathom Pharmaceuticals Reports Strong Growth with VOQUEZNA - TipRanks

Mar 06, 2025
pulisher
Mar 06, 2025

Phathom Pharmaceuticals: Strong Performance and Optimistic Outlook Amidst Patent Uncertainty - TipRanks

Mar 06, 2025
pulisher
Mar 06, 2025

Stifel maintains Buy on Phathom stock with $28 target - Investing.com India

Mar 06, 2025
pulisher
Mar 06, 2025

Stifel maintains Buy on Phathom stock with $28 target By Investing.com - Investing.com South Africa

Mar 06, 2025
pulisher
Mar 06, 2025

Earnings call transcript: Phathom Pharma Q4 2024 sees 81% revenue rise - Investing.com UK

Mar 06, 2025
pulisher
Mar 06, 2025

Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - GlobeNewswire

Mar 06, 2025
pulisher
Mar 06, 2025

Phathom Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 06, 2025
pulisher
Mar 06, 2025

Phathom Pharmaceuticals, Inc. SEC 10-K Report - TradingView

Mar 06, 2025
pulisher
Mar 06, 2025

Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - GlobeNewswire Inc.

Mar 06, 2025
pulisher
Mar 05, 2025

Earnings To Watch: Phathom Pharmaceuticals Inc (PHAT) Reports Q4 2024 Result - GuruFocus.com

Mar 05, 2025
pulisher
Mar 03, 2025

Phathom Pharmaceuticals stock hits 52-week low at $5.21 - Investing.com

Mar 03, 2025
pulisher
Mar 03, 2025

Phathom Pharmaceuticals stock hits 52-week low at $5.21 By Investing.com - Investing.com Canada

Mar 03, 2025
pulisher
Mar 01, 2025

(PHAT) Investment Analysis and Advice - Stock Traders Daily

Mar 01, 2025
pulisher
Feb 28, 2025

Phathom Pharmaceuticals (PHAT) Expected to Announce Earnings on Thursday - MarketBeat

Feb 28, 2025
pulisher
Feb 28, 2025

Cantor Fitzgerald Upgrades Phathom Pharmaceuticals (NASDAQ:PHAT) to Strong-Buy - MarketBeat

Feb 28, 2025
pulisher
Feb 27, 2025

Phathom Pharmaceuticals (PHAT) Projected to Post Quarterly Earnings on Thursday - Defense World

Feb 27, 2025
pulisher
Feb 25, 2025

Phathom Pharmaceuticals to Report Fourth Quarter and Full - GlobeNewswire

Feb 25, 2025
pulisher
Feb 24, 2025

Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on Thursday, March 6, 2025 - The Manila Times

Feb 24, 2025
pulisher
Feb 24, 2025

Phathom Pharmaceuticals to Host Conference Call on March 6, 2025, for Fourth Quarter and Full Year 2024 Financial Results - Nasdaq

Feb 24, 2025
pulisher
Feb 24, 2025

Can Phathom's VOQUEZNA Sales Drive Q4 Growth? Earnings Call Set for March 6 - StockTitan

Feb 24, 2025
pulisher
Feb 18, 2025

How to Take Advantage of moves in (PHAT) - Stock Traders Daily

Feb 18, 2025
pulisher
Feb 18, 2025

Phathom Pharmaceuticals CFO Molly Henderson sells shares worth $43,370 - MSN

Feb 18, 2025
pulisher
Feb 18, 2025

Cantor Fitzgerald Begins Coverage on Phathom Pharmaceuticals (NASDAQ:PHAT) - MarketBeat

Feb 18, 2025
pulisher
Feb 17, 2025

Phathom spikes as Cantor Fitzgerald bullish on IP claims - MSN

Feb 17, 2025
pulisher
Feb 16, 2025

Cantor Fitzgerald Initiates Coverage on Phathom Pharmaceuticals (NASDAQ:PHAT) - Defense World

Feb 16, 2025

Phathom Pharmaceuticals Inc Stock (PHAT) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Phathom Pharmaceuticals Inc Stock (PHAT) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Henderson Molly
CFO and CBO
Jan 21 '25
Sale
6.59
6,583
43,371
93,546
Nabulsi Azmi
Chief Operating Officer
Jan 21 '25
Sale
6.59
7,886
51,957
233,390
Curran Terrie
President and Chief Executive
Jan 21 '25
Sale
6.59
19,109
125,884
360,465
Nabulsi Azmi
Chief Operating Officer
Dec 19 '24
Sale
8.00
1,118
8,944
239,303
Henderson Molly
CFO and CBO
Dec 19 '24
Sale
8.00
1,291
10,328
98,156
KARBE FRANK
Director
Dec 13 '24
Buy
7.93
12,500
99,084
57,000
Parikh Asit
Director
Dec 13 '24
Buy
8.12
10,000
81,248
75,500
Nabulsi Azmi
Chief Operating Officer
Jul 15 '24
Sale
11.72
10,901
127,760
240,421
Henderson Molly
CFO and CBO
Jul 15 '24
Sale
11.72
4,325
50,689
99,447
Curran Terrie
President and Chief Executive
Jul 15 '24
Sale
11.72
33,848
396,699
377,734
$78.94
price up icon 2.53%
$318.85
price up icon 1.51%
$33.41
price up icon 0.00%
$20.11
price up icon 1.41%
$99.27
price up icon 0.31%
biotechnology ONC
$266.26
price up icon 1.87%
Cap:     |  Volume (24h):